LearnGlossaryMarketStocksSuperinvestorsSign in

ALVO

Alvotech

Healthcare · $1.9B market cap

Verdict

We can't put a fair value on ALVO right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth59.5% a year✓
Free cash flow growth—?
Return on invested capital-11.0%✗

Follow ALVO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ALVO. In Q1 2026, 1 trimmed. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$362K

97,982 shares

Moves in Q1 2026

Trimmed: Howard Marks

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works